FOXA2 and prostate neoplasm: In 2010, Ronai and his colleagues reported on the potential role of a hypoxia-mediated “FoxA2/HIF-1a” complex in driving NE phenotype in mouse prostate tumors, which is concordant with previous studies pointing out the preferential occurrence of FOXA2 expression in human NEPC (67).